D. J. Angiolillo (1), P. Capranzano (1), J. L. Ferreiro (1), M. Ueno (1), D. Capodanno (1), K. Dharmashankar (1), A. Darlington (1), S. Sumner (1), B. Desai (1), R. K. Charlton (2), L. C. Box (1), M. Zenni (1), L. A. Guzman (1), T. A. Bass (1)
(1) Division of Cardiology, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA; (2) Jacksonville Transplant Center, Shands Jacksonville, Jacksonville, Florida, USA
Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding. These clinical benefits have shown to be more pronounced in patients with diabetes mellitus (DM). However, it remains unknown whether cilostazol exerts different pharmacodynamic effects in patients with and without DM. This was a randomised, double-blind, placebo-controlled, cross-over pharmacodynamic study comparing platelet function in patients with and without DM on aspirin and clopidogrel therapy. Patients (n=111) were randomly assigned to either cilostazol 100 mg or placebo twice daily for 14 days and afterwards crossed-over treatment for another 14 days. Platelet function was performed at baseline, 14 days post-randomisation, and 14 days post-cross-over. Functional testing to assess P2Y12 signalling included flow cytometric analysis of phosphorylation status of vasodilator-stimulated phosphoprotein measured by P2Y12 reactivity index (PRI), light transmittance aggregometry and VerifyNow. Thrombin generation processes were also studied using thrombelastography. Significantly lower PRI values were observed following treatment with cilostazol compared with placebo both in DM and non-DM groups (p < 0.0001). The absolute between-treatment differences of PRI between groups was a 35.1% lower in patients with DM (p=0.039). Similar results were obtained using all other functional measures assessing P2Y12 signalling. Thrombin generation was not affected by cilostazol. Cilostazol reduces platelet reactivity both in patients with and without DM, although these pharmacodynamic effects are enhanced in patients with DM. Despite the marked platelet inhibition, cilostazol does not alter thrombin-mediated haemostatic processes, which may explain its ischaemic benefit without the increased risk of bleeding.
Diabetes Mellitus, Coronary artery disease, Platelets
M. Koehli 1,2 , D. Monbaron 1 , J. O. Prior2 , M. L. Calcagni 2, 3 , M. Fivaz-Arbane4 , J. C. Stauffer4 , R. C. Gaillard 1 , A. Bischof Delaloye2 , J. Ruiz1
Nuklearmedizin 2006 45 2: 74-81
Die Medizinische Welt 2003 54 5: 109-
Victor L. Serebruany1; Motoji Kogushi2; Daniela Dastros-Pitei3; Marcus Flather4; Deepak L. Bhatt5
Thromb Haemost 2009 102 1: 111-119
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...